Condition

Non-Clear Cell Renal Cell Carcinoma (nccRCC)

ClinicalTrials.gov condition label

Clinical trials2

Recruiting1

Common interventions11

Lead sponsors shown1

Clinical trials

2 shown

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · 2021-12-14

RECRUITING

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574 · 2026-07-30

ENROLLING_BY_INVITATION

Common interventions

NivolumabDRUG2PrednisoneDRUG2ZanzalintinibDRUG2AbirateroneDRUG1AtezolizumabDRUG1CabozantinibDRUG1DDI Probe CocktailDRUG1DocetaxelDRUG1EnzalutamideDRUG1IpilimumabDRUG1Nivolumab + RelatlimabDRUG1

Leading sponsors

Exelixis2

Trial status mix

ENROLLING_BY_INVITATION1

RECRUITING1

Phase mix

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.